ΔΎΉΟΦ±²₯

Meeting Coverage

AASLD

American Association for the Study of Liver Diseases

Novel Therapy Reduced Liver Fat, Improved Fibrosis in MASH

Liver fat reductions were sustained for up to a year with the thyroid hormone receptor agonist

AASLD over a photo of San Diego Convention Center in San Diego, CA.

Latest AASLD Meeting Coverage

'A Watershed Moment': GLP-1 Drug Succeeds in Late-Stage MASH Trial

First positive phase III study for a GLP-1 agonist in chronic liver disease

November 20, 2024
Tapered Steroid Dosing Safe, Effective in Severe Alcohol-Associated Hepatitis

Notably, tapering reduced the risk of infection compared with a fixed dose

November 20, 2024
New MELD Model Improves Access to Liver Transplant for Women

A greater proportion of women on the waitlist and undergoing transplant since adoption

November 19, 2024
Immunotherapy Shows Promise in Downstaging Liver Tumors Prior to Transplant

78% of patients in prospective study had tumor downstaging with immune checkpoint inhibitors

November 19, 2024
Fecal Therapy Shows Survival Benefit in Severe Alcoholic Hepatitis

Improved markers of disease severity as well in small trial of steroid-ineligible patients

November 18, 2024
PPAR Agonist Led to 'Clinically Meaningful' Improvement in PBC-Related Pruritus

Seladelpar also improved markers of disease activity versus placebo

November 15, 2023
Novel MASH Drug Reduces Liver Fat in Mid-Stage Trial

At highest dose, thyroid hormone receptor-beta agonist decreased liver fat content by 45%

November 15, 2023
Emergency Liver Transplant Effective for Severe Acute-on-Chronic Liver Failure

1-year survival reached 78% for patients who received an emergency transplant

November 14, 2023
Novel Drug Makes Its Case for Pretreated Primary Biliary Cholangitis

In randomized trial, oral elafibranor induced biochemical response at 1 year in 51% of patients

November 14, 2023
AKI Response Tied to Improved Survival for Patients Waiting on Liver Transplant

Results highlight the importance of prompt recognition and treatment of acute kidney injury

November 13, 2023
MASLD Predicted to Increase by 23% by Middle of the Century

AASLD president: "No way we are going to be able to transplant our way out of this"

November 12, 2023
Will Fresh Look at Obeticholic Acid Data in NASH Sway FDA?

Latest REGENERATE analysis comes on heels of REVERSE flop

November 11, 2022
Steroids and G-CSF Boost 90-Day Survival in Severe Alcoholic Hepatitis

Plus: Normothermic machine perfusion for liver transplants and Noom Weight for NASH

November 11, 2022
Novel Hepatitis B Drug Hints at Long-Term 'Functional Cure' for Some in Early Trial

With 10% efficacy at 6 months post-treatment, a finite HBV treatment may be on the horizon

November 10, 2022